Previous 10 | Next 10 |
CAMBRIDGE, Mass. , May 8, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that Jeff Albers , Blueprint Medicines' Chief Ex...
CAMBRIDGE, Mass. , May 2, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that it will host a live conference call and webcast at 8:30 a.m...
Source: Shutterstock The stock market has continued to edge higher and the two major indexes, the Nasdaq ( QQQ ) and S&P 500 ( SPY ), touched the all-time high milestone last week. The steady gain reflects a diminishing concern relating to the pace of a global economic slowdown, as m...
By Jonathan Liss Listen and subscribe to the Marketplace Roundtable on these podcast platforms: iTunes/Apple Podcasts Spotify Stitcher Jonathan Faison doesn't want prospective biotech investors to think that they need some sort of "special sauce" to succeed...
Sometime back, we covered Deciphera ( DCPH ), which is targeting tyrosine kinase inhibitors or TKI resistance through inhibition of "switch pocket," a specific area which stabilizes the active kinase. Inhibiting this destabilizes the active kinase, thus bypassing secondary kinase resistance....
Blueprint Medicines (NASDAQ: BPMC ) initiated with Overweight rating and $112 (34% upside) price target at Morgan Stanley. More news on: Blueprint Medicines Corporation, iRhythm Technologies, Inc., Incyte Corporation, Healthcare stocks news, Stocks on the move, , Read more ...
Blueprint Medicines (NASDAQ: BPMC ) prices public offering of 4,054,054 common stock at a price of $74.00/share. More news on: Blueprint Medicines Corporation, Healthcare stocks news, Read more ...
Blueprint Medicines (NASDAQ: BPMC ) announces plans to speed development of pipeline candidates avapritinib, BLU-667 and BLU-782. More news on: Blueprint Medicines Corporation, Healthcare stocks news, Stocks on the move, Read more ...
CAMBRIDGE, Mass. , March 27, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced plans to expedite development of avapritinib, BLU-667 and BLU-782 b...
Deciphera Pharmaceuticals ( DCPH ) is a small company with a pipeline of small molecules targeting various causes of cancer. Lead candidate Ripretinib is an orally administered kinase switch control inhibitor being developed for the treatment of "gastrointestinal stromal tumors (GIST), advan...
News, Short Squeeze, Breakout and More Instantly...
Blueprint Medicines Corporation Company Name:
BPMC Stock Symbol:
NASDAQ Market:
Blueprint Medicines Corporation Website:
2024-07-29 07:15:06 ET Barclays analyst issues EQUAL-WEIGHT recommendation for BPMC on July 29, 2024 05:43AM ET. The previous analyst recommendation was Equal-Weight. BPMC was trading at $112.19 at issue of the analyst recommendation. The overall analyst consensus : BUY....
2024-07-29 07:00:10 ET Peter Lawson from Barclays issued a price target of $105.00 for BPMC on 2024-07-29 05:43:00. The adjusted price target was set to $105.00. At the time of the announcement, BPMC was trading at $112.19. The overall price target consensus is at $100.7...
Blueprint Medicines to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024 PR Newswire CAMBRIDGE, Mass. , July 18, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call an...